Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Atezolizumab/bevacizumab/methylprednisolone

Pneumonitis, acute respiratory distress syndrome and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Cho SH, et al. Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: A case report. World Journal of Gastrointestinal Oncology 15 : 892-901, No. 5, Jan 2023. Available from: URL: https://www.wjgnet.com/1948-5204/e-journal.htm Cho SH, et al. Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: A case report. World Journal of Gastrointestinal Oncology 15 : 892-901, No. 5, Jan 2023. Available from: URL: https://​www.​wjgnet.​com/​1948-5204/​e-journal.​htm
Metadaten
Titel
Atezolizumab/bevacizumab/methylprednisolone
Pneumonitis, acute respiratory distress syndrome and lack of efficacy: case report
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41753-0

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drug

Case report

Lithium

Case report

Cabozantinib